Nina Kjellson is a General Partner at Canaan Partners, where she invests in biopharma and digital health companies that serve unmet therapeutic and access needs. She is a director of Tyra Biosciences (NADSAQ: TYRA), Panacea Acquisition II (NASDAQ: PANA) and of private biopharmaceutical firms, PACT, Rondo, Sardona, Tizona (optioned by Gilead), and Trishula (optioned by AbbVie). Prior to Canaan, Nina was a General Partner at InterWest Partners where she supported many companies including Aspreva (ASPV; acqd by Galenica); Cidara (CDTX); CNS Therapeutics (acqd by Mallinckrodt), Eiger (EIGR), Labrys (acqd by Teva) Novacardia (acqd by Merck), Paratek (PRTK), Tesaro (TSRX, acqd by GSK) and Trius (TRSX, acqd by Cubist). As a founder of WoVen: Women Who Venture, Nina is a vocal advocate for women entrepreneurs and investors. She is a Health Innovators Fellow of the Aspen Institute and serves as a director of Essential Access Health, Life Sciences Cares Bay Area, Girl Effect and is a member of the Leadership Council of the Oliver Wyman Health Innovation Center. She holds a B.A. in human biology from Stanford University.